Erik Mittra YOU? Author Swipe

Last 10y

Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial Open

Lisa Bodei, Marta Cremonesi, Mahila Ferrari, Erik Mittra, Harshad Kulkarni , et al. · 2025

This substudy of the phase III NETTER-1 trial evaluated [¹⁷⁷Lu]Lu-DOTATATE (hereafter ¹⁷⁷Lu-DOTATATE) for advanced midgut neuroendocrine tumors and aimed to assess dosimetry of a standard 4-cycle protocol and any pote…

A model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques Open

Helen L. Wu, Whitney C. Weber, Courtney Waytashek, Carla Boyle, Jason S. Reed , et al. · 2024

Immunocompromised individuals are at risk for developing lymphocryptovirus-associated lymphoproliferative diseases, such as Epstein Barr virus (EBV)-associated B cell lymphomas and post-transplant lymphoproliferative disorder (PTLD). We pr…

Illuminating immunotherapy response via precision T cell-targeted PET imaging Open

Sarah Glazer, Shivaani Kummar, Erik Mittra · 2024

Traditionally, immunotherapy agent selection and treatment strategies are guided by biopsy-based histological information. However, biopsies are limited in that they are invasive, provide static information regarding the tumor immune micro…

Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors Open

Aman Chauhan, Kelley Chan, Þorvarður R. Hálfdánarson, Andrew M. Bellizzi, Guido Rindi , et al. · 2024

The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP‐NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. …

Clinical [18F]FSPG Positron Emission Tomography Imaging Reveals Heterogeneity in Tumor-Associated System xc− Activity Open

Amy R. Sharkey, Norman Koglin, Erik Mittra, Sangwon Han, Gary Cook , et al. · 2024

Background: (4S)-4-(3-[18F]fluoropropyl)-L-glutamic acid ([18F]FSPG) positron emission tomography/computed tomography (PET/CT) provides a readout of system xc− transport activity and has been used for cancer detection in clinical studies o…

Establishing a robust radioligand therapy program: A practical approach for North American centers Open

Erik Mittra, Rebecca Wong, Celeste Winters, Adam Brown, Shondra Murley , et al. · 2024

Radioligand therapy (RLT) is a targeted approach to treating cancer that has been shown to be safe and effective in a variety of disease states, including gastroenteropancreatic neuroendocrine tumors, lymphoma, and most recently, advanced …

Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry Open

Catherine Meyer, László Szidonya, Celeste Winters, Anna Mench, Nadine Mallak , et al. · 2023

PSMA-targeted radiopharmaceutical therapy is an established treatment option for metastatic castration-resistant prostate cancer (mCRPC). However, response rates and duration using 177 Lu-PSMA-617 vary considerably between patients. Quanti…

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms Open

Jennifer R. Eads, Þorvarður R. Hálfdánarson, Tim Asmis, Andrew M Belizzi, Emily K. Bergsland , et al. · 2023

High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practiti…

Supplementary Tables 1 - 2 from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

PDF file, 72K, S1: Clinical safety laboratory parameters; S2: Tissue distribution of 18FFSPG.

Supplementary Figure Legend from Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI Open

Erik Mittra, Hua Fan-Minogue, Frank I. Lin, Jason Karamchandani, Venkataraman Sriram , et al. · 2023

Supplementary Figure Legend - PDF file 60K, Supplementary figure legend

Supplementary Figure Legend from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

PDF file, 76K, includes movie legends.

Erik Mittra, Hua Fan-Minogue, Frank I. Lin, Jason Karamchandani, Venkataraman Sriram , et al. · 2023

Supplementary Figure Legend - PDF file 60K, Supplementary figure legend

Supplementary Movie 2A from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

AVI, 146K, Maximum intensity projection of 18FFDG in a breast cancer patient (Patient 13).

Supplementary Movie 1A from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

AVI, 167K, Maximum intensity projection of 18FFDG in a lung cancer patient (Patient 2).

Supplementary Tables from Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI Open

Erik Mittra, Hua Fan-Minogue, Frank I. Lin, Jason Karamchandani, Venkataraman Sriram , et al. · 2023

Supplementary Tables - PDF file 86K, Supplementary Table 1. Overall results of 2nd experiment shown as percent change from baseline by experimental group: Control, Low Dose, and High Dose. Supplementary Table 2. Mitotic activity and Ki-67 …

Data from Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI Open

Erik Mittra, Hua Fan-Minogue, Frank I. Lin, Jason Karamchandani, Venkataraman Sriram , et al. · 2023

Purpose: Ficlatuzumab is a novel therapeutic agent targeting the hepatocyte growth factor (HGF)/c-MET pathway. We summarize extensive preclinical work using this agent in a mouse brain orthotopic model of glioblastoma.Experimenta…

View article: Supplementary Movie 1B from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Supplementary Movie 1B from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

AVI, 180K, Maximum intensity projection of 18FFSPG in a lung cancer patient (Patient 2).

View article: Supplementary Figures 1 - 5 from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Supplementary Figures 1 - 5 from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

PDF file, 358K, S1: System xC� and CD44 in glutathione biosynthesis and the cysteine-cystine redox cycle; S2: 18FFSPG distribution in normal organs and cancer; S3: Correlation between 18FFDG and 18FFSPG; S4: 18FFDG and 18FFSPG PET in a bre…

View article: Supplementary Movie 1A from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Supplementary Movie 1A from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

AVI, 167K, Maximum intensity projection of 18FFDG in a lung cancer patient (Patient 2).

View article: Data from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Data from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

Purpose: (4S)-4-(3-[¹⁸F]fluoropropyl)-l-glutamate (BAY 94-9392, alias [¹⁸F]FSPG) is a new tracer to image x_C⁻ transporter activity with positron emission tomography (PET). We aimed …

View article: Supplementary Figure Legend from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Supplementary Figure Legend from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

PDF file, 76K, includes movie legends.

View article: Supplementary Tables from Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI

Supplementary Tables from Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI Open

Erik Mittra, Hua Fan-Minogue, Frank I. Lin, Jason Karamchandani, Venkataraman Sriram , et al. · 2023

Supplementary Tables - PDF file 86K, Supplementary Table 1. Overall results of 2nd experiment shown as percent change from baseline by experimental group: Control, Low Dose, and High Dose. Supplementary Table 2. Mitotic activity and Ki-67 …

View article: Data from Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI

Data from Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI Open

Erik Mittra, Hua Fan-Minogue, Frank I. Lin, Jason Karamchandani, Venkataraman Sriram , et al. · 2023

Purpose: Ficlatuzumab is a novel therapeutic agent targeting the hepatocyte growth factor (HGF)/c-MET pathway. We summarize extensive preclinical work using this agent in a mouse brain orthotopic model of glioblastoma.Experimenta…

View article: Supplementary Movie 2B from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Supplementary Movie 2B from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

AVI, 161K, Maximum intensity projection of 18FFSPG in a breast cancer patient (Patient 13).

View article: Supplementary Movie 1B from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Supplementary Movie 1B from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

AVI, 180K, Maximum intensity projection of 18FFSPG in a lung cancer patient (Patient 2).

View article: Supplementary Tables 1 - 2 from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Supplementary Tables 1 - 2 from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

PDF file, 72K, S1: Clinical safety laboratory parameters; S2: Tissue distribution of 18FFSPG.

View article: Data from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Data from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

Purpose: (4S)-4-(3-[¹⁸F]fluoropropyl)-l-glutamate (BAY 94-9392, alias [¹⁸F]FSPG) is a new tracer to image x_C⁻ transporter activity with positron emission tomography (PET). We aimed …

View article: Supplementary Figures from Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI

Supplementary Figures from Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI Open

Erik Mittra, Hua Fan-Minogue, Frank I. Lin, Jason Karamchandani, Venkataraman Sriram , et al. · 2023

Supplementary Figures - PDF file 110K, Supplementary Figure 1. Dose titration curves of ficlatuzumab. The numbers in parenthesis are the median survival in days. Supplementary Figure 2. combination therapy of ficlatuzumab and temozolomide …

View article: Supplementary Figures 1 - 5 from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Supplementary Figures 1 - 5 from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

PDF file, 358K, S1: System xC� and CD44 in glutathione biosynthesis and the cysteine-cystine redox cycle; S2: 18FFSPG distribution in normal organs and cancer; S3: Correlation between 18FFDG and 18FFSPG; S4: 18FFDG and 18FFSPG PET in a bre…

View article: Supplementary Movie 2A from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Supplementary Movie 2A from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Open

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong , et al. · 2023

AVI, 146K, Maximum intensity projection of 18FFDG in a breast cancer patient (Patient 13).